Recent developments in retinal gene therapy have led to the successful treatment of patients with Leber’s congenital amaurosis (LCA) due to mutations in RPE65[1], [2], [3], [4], [5], [6], [7]. This evidence concerns the gene RPE65 and Leber congenital amaurosis.